Beigene Ltd

BeiGene, Ltd. is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. The Company has an oncology pipeline of more than 50 investigational assets. Its products include BRUKINSA, TEVIMBRA, XGEVA, BLINCYTO, KYPROLIS, POBEVCY, and others. BRUKINSA is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). TEVIMBRA is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is engaged in the sale of XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen and POBEVCY in China under a license from Bio-Thera. The Company’s pipeline products include Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, Xaluritamig, and others.